奥曲肽联合腹水浓缩回输在肝硬化腹水诊治中的临床观察  

Clinical observation of Octreotide combined with Reinfusion of concentrated ascites in treatment of ascites due to liver cirrhosis

作　　者：文正燕 王莉[2] 

机构地区：[1]河南省新乡市传染病医院,河南新乡453000 [2]河南省新乡医学院第三附属医院生殖中心

出　　处：《中国民康医学》2014年第11期20-22,共3页Medical Journal of Chinese People’s Health

摘　　要：目的:分析比较肝硬化腹水诊治中奥曲肽和腹水浓缩回输腹腔的临床效果。方法:随机将60例肝硬化腹水患者分为对照组和观察组,对照组患者行腹水超滤浓缩回输腹腔和常规的保肝、补充白蛋白和血浆、利尿等治疗,治疗组患者在对照组治疗的基础上行奥曲肽注射治疗,并观察两组临床治疗效果。结果:治疗组患者治疗的总有效率为90%,对照组患者治疗的总有效率为70.0%,治疗组患者平均住院时间为(10.2±2.6)d,对照组患者平均住院时间为(14.6±2.4)d,两组治疗总有效率、住院时间比较差异有统计学意义(P<0.05)。结论:奥曲肽和腹水浓缩回输腹腔联合应用在肝硬化腹水治疗中总有效率高,安全性好,住院时间短,效果显著,值得临床推广使用。Objective：To analyze application effect of octreotide and reinfusion of concentrated ascite in treatment of ascites due to liver cirrhosis. Methods：60 cases with ascites due to liver cirrhosis were randomly divided into observation group and control group, wherein the control group was treated with reinfusion of ultra-filtered and concentrated ascites into abdominal cavity and conven-tional protecting liver, supplement of albumin and plasma, and diuretic therapy, while the treatment group was given octreotide injec-tion treatment based on the treatments of control group. The clinical therapeutic effects of the two groups were observed. Results： The total effective rate of treatment group was 90% , whereas that of control group was 70% ; the average hospitalization time for the patients in treatment group was （10. 2±2. 6） d, whereas that for the patients in control group was （14. 6±2. 4） d; and there were statistical differences in the total effective rate and hospitalization time between the two groups （P〈0. 05）. Conclusions： Octreotide combined with reinfusion of concentrated ascites in the treatment of ascites due to liver cirrhosis has a high total effective rate, high safety, short hospitalization time, and significant effect, and is worthy of clinical use.

关 键 词：腹水浓缩回输腹腔 奥曲肽 肝硬化腹水 应用 

分 类 号：R575.2[医药卫生—消化系统]